Human CD20 Virus-Like Particles

CD20 is a transmembrane protein primarily expressed on the surface of B lymphocytes, playing a key role in B cell development and regulation of immune responses. As a non-glycosylated phosphoprotein, CD20 participates in the transmembrane flux of calcium ions, which is crucial for B cell activation and proliferation. CD20 is expressed exclusively on pre-B cells, mature B cells, and malignant B cells, but not on plasma cells or hematopoietic stem cells. This makes it an ideal therapeutic target for B cell-related malignancies and autoimmune diseases. Monoclonal antibodies such as rituximab, ofatumumab, and obinutuzumab have been developed to target CD20 and cause B cell depletion through mechanisms such as antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct induction of apoptosis.

CD20 virus-like particles (VLPs) are innovative nanoscale structures designed to mimic the native conformation of CD20 on the surface of non-infectious viral particles. VLPs are self-assembling platforms that contain no viral genetic material, ensuring safety while retaining the immunogenicity and structural integrity of the native virus. By incorporating CD20 into VLPs, researchers can construct highly immunogenic vaccines or therapeutics capable of eliciting a robust immune response against CD20-expressing B cells. These particles are particularly promising for cancer immunotherapy because they can be designed to present CD20 in its native form, enhancing recognition and targeting by the immune system. Furthermore, CD20 VLPs can be functionalized with adjuvants or other immunomodulatory molecules to further enhance their efficacy. Beyond their therapeutic applications, CD20 VLPs also serve as valuable tools for studying B cell biology, antibody development, and immune evasion mechanisms.